Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Completed · Phase 2 · Has a placebo group
Conditions studied: Spinal and Bulbar Muscular Atrophy
In brief
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
Key facts
- Study ID
- NCT02024932
- Run by
- Novartis Pharmaceuticals
- People needed
- 37
- Starts
- 2014-02-04
- Expected to finish
- 2016-04-13
- Last updated by the study team
- 2021-01-05
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Orange, California, United States
- National Institutes of Health — Bethesda, Maryland, United States
- Novartis Investigative Site — Columbus, Ohio, United States
- Novartis Investigative Site — Copenhagen, Denmark
- Novartis Investigative Site — Ulm, Germany
- Novartis Investigative Site — Padova, PD, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.